Online Impact
Statistics from Altmetric.com
ARTICLE USAGE
Cited By
Article Information
PubMed
Published By
Print ISSN
Online ISSN
History
- Received April 28, 2019
- Revision received June 28, 2019
- Accepted August 2, 2019
- Published first August 8, 2019.
Article Versions
- You are currently viewing a Previous version of this article (August 8, 2019 - 06:06).
- View the most recent version of this article
Copyright & Usage
Copyright ©2019, American Association for Cancer Research.
Author Information
- Shigehiro Koganemaru1,
- Yasutoshi Kuboki1,*,
- Yoshikatsu Koga2,
- Takashi Kojima3,
- Mayumi Yamauchi3,
- Naoyuki Maeda4,
- Takashi Kagari5,
- Kenji Hirotani6,
- Masahiro Yasunaga2,
- Yasuhiro Matsumura2, and
- Toshihiko Doi1
- 1Department of Experimental Therapeutics, National Cancer Center Hospital East
- 2Division of Developmental Therapeutics, National Cancer Center Hospital East
- 3Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East
- 4Biomarker & Translational Research Department, Daiichi Sankyo Co., Ltd.
- 5Oncology Research Laboratories I, Daiichi Sankyo Co., Ltd.
- 6Oncology Clinical Development Department, DAIICHI SANKYO CO.,LTD.
- ↵* Corresponding Author:
Yasutoshi Kuboki, Department of Experimental Therapeutics, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan. E-mail: ykuboki{at}east.ncc.go.jp
Published OnlineFirst August 8, 2019
doi: 10.1158/1535-7163.MCT-19-0452
U3-1402, a novel HER3-targeting antibody-drug conjugate, for the treatment of Colorectal Cancer
Jump to section
Advertisement